Nanoparticle formulation enhanced protective immunity provoked by PYGPI8p-transamidase related protein (PyTAM) DNA vaccine in Plasmodium yoelii malaria model

Chérif, Mahamoud Sama; Shuaibu, Mohammed Nasir; Kodama, Yukinobu; Kurosaki, Tomoaki; Helegbe, Gideon Kofi; Kikuchi, Mihoko; Ichinose, Akitada; Yanagi, Tetsuo; Sasaki, Hidetada; Yui, Katsuyuki; Huy, Nguyen Tien; Karbwang, Juntra; Hirayama, Kenji

doi:10.1016/j.vaccine.2014.01.005

Cited by 15 publications

(21 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors suggest the improved survival rates may be a result of an improved DNA expression vector. Using an alternative target, the PyG18p transimidase related protein, similar results were obtained [ 88 ]. The authors point to previous work to conclude that effective T cell immunity was the most important correlate for protection against this antigen.…”

Section: Particle Use In Malaria Vaccine Developmentsupporting

confidence: 59%

The Use of Synthetic Carriers in Malaria Vaccine Design

2015

View full text Add to dashboard Cite

Malaria vaccine research has been ongoing since the 1980s with limited success. However, recent improvements in our understanding of the immune responses required to combat each stage of infection will allow for intelligent design of both antigens and their associated delivery vaccine vehicles/vectors. Synthetic carriers (also known as vectors) are usually particulate and have multiple properties, which can be varied to control how an associated vaccine interacts with the host, and consequently how the immune response develops. This review comprehensively analyzes both historical and recent studies in which synthetic carriers are used to deliver malaria vaccines. Furthermore, the requirements for a synthetic carrier, such as size, charge, and surface chemistry are reviewed in order to understand the design of effective particle-based vaccines against malaria, as well as providing general insights. Synthetic carriers have the ability to alter and direct the immune response, and a better control of particle properties will facilitate improved vaccine design in the near future.

show abstract

Section: Particle Use In Malaria Vaccine Developmentsupporting

confidence: 59%

The Use of Synthetic Carriers in Malaria Vaccine Design

2015

View full text Add to dashboard Cite

show abstract

“…For example, vaccination against the thrombospondin-related anonymous protein/sporozoite surface protein-2 (TRAP/SSP2) induces high-frequency TRAP/SSP2specific CD8 + T cells in mice (80) and humans (81) that can kill infected liver cells (82). However, beyond CSP, TRAP/SSP2, and relatively few partially protective Ags (83)(84)(85)(86)(87)(88)(89)(90), most of the thousands of PE proteins remain unstudied as vaccine Ags. Thus, a renewed interest in discovery of protective CD8 + T cell Ags may be warranted.…”

Section: Discussionmentioning

confidence: 99%

Prime-and-Trap Malaria Vaccination To Generate Protective CD8+ Liver-Resident Memory T Cells

Olsen

Stone

Chuenchob

et al. 2018

The Journal of Immunology

View full text Add to dashboard Cite

Tissue-resident memory CD8 T (Trm) cells in the liver are critical for long-term protection against pre-erythrocytic infection. Such protection can usually be induced with three to five doses of i.v. administered radiation-attenuated sporozoites (RAS). To simplify and accelerate vaccination, we tested a DNA vaccine designed to induce potent T cell responses against the SYVPSAEQI epitope of circumsporozoite protein. In a heterologous "prime-and-trap" regimen, priming using gene gun-administered DNA and boosting with one dose of RAS attracted expanding Ag-specific CD8 T cell populations to the liver, where they became Trm cells. Vaccinated in this manner, BALB/c mice were completely protected against challenge, an outcome not reliably achieved following one dose of RAS or following DNA-only vaccination. This study demonstrates that the combination of CD8 T cell priming by DNA and boosting with liver-homing RAS enhances formation of a completely protective liver Trm cell response and suggests novel approaches for enhancing T cell-based pre-erythrocytic malaria vaccines.

show abstract

“…Another P. yoelii antigen, PyTmp1, could induce immune responses that reduced liver stage parasite burden in vivo ( Chen et al, 2014 ), and three other P. yoelii antigens in combination (but not individually) could induce sterile immunity in a high proportion of immunized mice ( Limbach et al, 2011 ). Two P. yoelii blood stage antigens, PyTAM and Py01157, have been also associated with partial protection in the murine model ( Zhang et al, 2012 ; Cherif et al, 2014 ; Table 4 ). These data support the potential of genome-based antigen discovery.…”

Section: Genome-based Vaccine Designmentioning

confidence: 99%

The case for a rational genome-based vaccine against malaria

Proietti

Doolan

2015

Front. Microbiol.

View full text Add to dashboard Cite

Historically, vaccines have been designed to mimic the immunity induced by natural exposure to the target pathogen, but this approach has not been effective for any parasitic pathogen of humans or complex pathogens that cause chronic disease in humans, such as Plasmodium. Despite intense efforts by many laboratories around the world on different aspects of Plasmodium spp. molecular and cell biology, epidemiology and immunology, progress towards the goal of an effective malaria vaccine has been disappointing. The premise of rational vaccine design is to induce the desired immune response against the key pathogen antigens or epitopes targeted by protective immune responses. We advocate that development of an optimally efficacious malaria vaccine will need to improve on nature, and that this can be accomplished by rational vaccine design facilitated by mining genomic, proteomic and transcriptomic datasets in the context of relevant biological function. In our opinion, modern genome-based rational vaccine design offers enormous potential above and beyond that of whole-organism vaccines approaches established over 200 years ago where immunity is likely suboptimal due to the many genetic and immunological host-parasite adaptations evolved to allow the Plasmodium parasite to coexist in the human host, and which are associated with logistic and regulatory hurdles for production and delivery.

show abstract

Nanoparticle formulation enhanced protective immunity provoked by PYGPI8p-transamidase related protein (PyTAM) DNA vaccine in Plasmodium yoelii malaria model

Cited by 15 publications

References 51 publications

The Use of Synthetic Carriers in Malaria Vaccine Design

The Use of Synthetic Carriers in Malaria Vaccine Design

Prime-and-Trap Malaria Vaccination To Generate Protective CD8+ Liver-Resident Memory T Cells

The case for a rational genome-based vaccine against malaria

Contact Info

Product

Resources

About